Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): review decision - December 2014 information

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appendix A - GE decision paper - December 2014

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appendix A - GE decision paper - December 2014 (PDF 496 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): review proposal october 2014 information

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appendix a - provisional matrix of stakeholders

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appendix a - provisional matrix of stakeholders (PDF 100 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appendix b - proposal paper presented to the Institute's Guidance Executive

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appendix b - proposal paper presented to the Institute's Guidance Executive (PDF 365 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): EIA form

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appeal  information

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appeal decision

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appeal decision (PDF 220 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): notice of appeal information

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): register to attend the appeal information

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appeal announcement information

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche - appeal received

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche - appeal received (PDF 240 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche - initial scrutiny letter

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche - initial scrutiny letter (PDF 45 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche - response to scrutiny letter

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche - response to scrutiny letter (PDF 66 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche - final scrutiny letter

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): final appraisal determination information

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): final appraisal determination

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): final appraisal determination (PDF 272 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): response to consultee, commentator and public comments on the ACD and comments from website consultation

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 210 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): response to comments on the second Appraisal Consultation document (ACD2) from Liverpool Reviews and Implementation Group

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): response to comments on the second Appraisal Consultation document (ACD2) from Liverpool Reviews and Implementation Group (PDF 277 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): consultee and commentator comments on the ACD

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from Roche

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from Roche (PDF 344 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from the Roy Castle Lung Cancer Foundation

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from the Roy Castle Lung Cancer Foundation (PDF 65 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from the British Thoracic Society

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from the British Thoracic Society (PDF 64 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from the Royal College of Nursing

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from the Royal College of Nursing (PDF 55 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from NCRI/Royal College of Physicians/RCR/ACP/JCCO

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from NCRI/Royal College of Physicians/RCR/ACP/JCCO (PDF 15 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from NHS Cornwall and Isles of Scilly

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from NHS Cornwall and Isles of Scilly (PDF 162 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from the Commissioning Support Appraisals Service

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from the Commissioning Support Appraisals Service (PDF 83 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from Eli Lilly

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from Eli Lilly (PDF 22 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from the British Thoracic Oncology Group

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from the British Thoracic Oncology Group (PDF 4.8 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comments on the ACD2 through web consultation

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appraisal consultation 2

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appraisal consultation document information

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): non-manufacturer comments on the appraisal consultation document

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roy Castle Lung Cancer Foundation

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roy Castle Lung Cancer Foundation (PDF 52 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): British Thoracic Society

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): British Thoracic Society (PDF 3.3 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Royal College of Nursing

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Royal College of Nursing (PDF 49 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Joint response from NCRI / Royal College of Physicians, RCR, ACP, JCCO

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Joint response from NCRI / Royal College of Physicians, RCR, ACP, JCCO (PDF 56 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Cornwall and the Isles of Scilly PCT

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Cornwall and the Isles of Scilly PCT (PDF 98 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Dudley PCT

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Dudley PCT (PDF 29 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Eli Lilly

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Eli Lilly (PDF 113 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche (PDF 149 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): manufacturer supplementary evidence

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche supplementary evidence

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche supplementary evidence (PDF 863 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche analysis

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche analysis (PDF 427 KB)

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): addendum to Evidence Review Group report on Roche supplementary evidence

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appraisal consultation

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appraisal consultation document information

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): evaluation report

Pre-meeting briefing

Pre-meeting briefing (PDF 270 KB)

Evidence Review Group report

Original Evidence Review Group report

Original Evidence Review Group report (PDF 949 KB)

Manufacturer's factual accuracy check of the Evidence Review Group report

Manufacturer's factual accuracy check of the Evidence Review Group report (PDF 113 KB)

Revised Evidence Review Group report, after factual accuracy check

Revised Evidence Review Group report, after factual accuracy check (PDF 981 KB)

ERG technical details of amendments made to manufacturers model - part A

ERG technical details of amendments made to manufacturers model - part A (PDF 66 KB)

ERG technical details of amendments made to manufacturers model - part B

ERG technical details of amendments made to manufacturers model - part B (PDF 169 KB)

NICE clarification letter with manufacturer's response

NICE clarification letter with manufacturer's response (PDF 223 KB)

Patient Access Scheme

Manufacturer's Patient Access Scheme submission

Manufacturer's Patient Access Scheme submission (PDF 327 KB)

Department of Health approval for Patient Access Scheme

Department of Health approval for Patient Access Scheme (PDF 40 KB)

Non-manufacturer submissions

Royal College of Physicians

Royal College of Physicians (PDF 71 KB)

NHS Cornwall and Isles of Scilly

NHS Cornwall and Isles of Scilly (PDF 67 KB)

Expert written personal statements

Ferry

Ferry (PDF 96 KB)

Mulatero

Mulatero (PDF 210 KB)

Parry

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): response to consultee and commentator comments on the provisional matrix

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): response to consultee and commentator comments on the draft scope

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): final scope 

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): draft scope

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): provisional matrix